This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
A CRA expert provided strategic consulting expertise regarding the suitability of various statistical tools and techniques that might be leveraged to assess the efficacy of a new pharmaceutical for a rare disease.
The CRA expert reviewed data from a variety of existing studies and analyzed limitations and opportunities regarding the use of such data. Client relied upon CRA’s analysis for business decision-making and negotiation purposes.
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...
CRA’s Michal Malkiewicz recently joined Eli Mazour’s Clause 8 podcast alongside Mike Pellegrino (Pellegrino & Associates, LLC) and Alejandra Loaiza Delgado...
Our fast-paced, highly practical format ensures that you will receive a complete look at what is taking place, key trends, and expert analysis from our...
Benno Buehler is a panelist during the session titled “Improving transparency at the interface between patents and standards.” This session will introduce the...
